Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Giessen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with histological verified CD20-positive B-Cell-Lymphomas of the following entities:
Follicular lymphoma grade 1 and 2
Immunocytoma and lymphoplasmocytic lymphoma
Marginal zone lymphoma, nodal and generalised
Mantle cell lymphoma
lymphocytic lymphoma (CLL without leucaemic characteristics)
non-specified/classified lymphomas of low malignancy
Recurrent disease (remission duration minimum 3 months), independent of type or quantity of prior therapies, except of Rituximab containing regimens, or if remission duration is \> 1 year after Rituximab containing regimen, or refractory to prior therapy (progression under therapy or during 3 months after completion), except refractory disease to purin analogs or Bendamustine
Need for therapy, except mantle cell lymphomas
Stadium II (bulky disease, 7.5 cm), II or IV
Written informed consent
Performance status WHO 0-2
Histology not older than 6 months
You may not be if
Patients not establishing all above mentioned prerequisites
Option of a primary, potentially curative radiation therapy
Patients refractory to Rituximab containing regimens
Comorbidities excluding a study conform therapy:
heart attack during the last 6 months severe, medicinal not adjustable hypertonia severe functional defects of the heart (NYHA III or IV) lung (WHO grade III or IV) liver or kidney (creatinine \> 2 mg/dl, GOT + GPT or bilirubin 3 x ULN, except caused by lymphoma
Active auto immunohemolytic anemia (AIHA)
HIV positive patients
Active hepatitis infection
Severe psychiatric diseases
No compliance or non-compliance to be expected
Pregnant or breast feeding women
Anamnestic malignancies or secondary malignancies, not proven
Cured/curable by surgery
Clareo Health | Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab
